Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs

Target entity: Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs
Context triple: [ICH E2C, fullName, Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs]

• A. ICH E2A Clinical Safety Data Management
  ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
• B. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
  The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
• C. Conditional Marketing Authorization by European Medicines Agency
  Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
• D. Statistics in Biopharmaceutical Research
  Statistics in Biopharmaceutical Research is a peer-reviewed journal focusing on the development and application of statistical methods in pharmaceutical, biotechnology, and medical product research.
• E. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
  ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs
Target entity description: Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs (ICH E2C) is an international guideline that standardizes the format, content, and timing of periodic safety reports submitted by marketing authorization holders to monitor and communicate the ongoing safety profile of approved medicines.

• A. ICH E2A Clinical Safety Data Management
  ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
• B. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
  The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
• C. Conditional Marketing Authorization by European Medicines Agency
  Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
• D. Statistics in Biopharmaceutical Research
  Statistics in Biopharmaceutical Research is a peer-reviewed journal focusing on the development and application of statistical methods in pharmaceutical, biotechnology, and medical product research.
• E. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
  ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
• F. None of above. chosen